Moleculin Biotech (MBRX) just unveiled an announcement. Moleculin Biotech, Inc. has announced the upcoming issuance of a significant new patent, titled “Preparation of Preliposomal Annamycin Lyophilizate,” granted by the United
Moleculin Biotech (MBRX) just unveiled an announcement. Moleculin Biotech, Inc. has announced the upcoming issuance of a significant new patent, titled “Preparation of Preliposomal Annamycin Lyophilizate,” granted by the United
Moleculin Biotech announced it has received an Issue Notification from the United States Patent and Trademark Office, or USPTO, for U.S. Patent number 11,951,118 titled, “Preparation of Preliposomal Annamycin Lyophilizate”
Maxim הורידו את מחיר היעד של Moleculin Biotech מ-45 ליש”ט ל-20 ליש”ט אך עדיין ממליצים על רכישת המניות. הם מצפים שהחברה תזדקק למימון נוסף, אשר עלול לדלל את ערכן של
Maxim lowered the firm’s price target on Moleculin Biotech to $20 from $45 and keeps a Buy rating on the shares. The firm is citing expectations of additional dilution associated
Moleculin Biotech (MBRX) just unveiled an update. Moleculin Biotech, Inc. has released a new corporate presentation on its website, designed to provide current and potential investors with insights into the